Education & Resources for Oncology Nurses – IMFINZI® (durvalumab)
Long-Term Side Effects of Immune Checkpoint Inhibitors - NCI
Endocrinopathies from checkpoint inhibitors: Incidence, outcomes, and management | Cleveland Clinic Journal of Medicine
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy - ScienceDirect
Frontiers | First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
Durvalumab - Wikipedia
Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA | Clinical Drug Investigation
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma | NEJM Evidence
Diagnostics | Free Full-Text | Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer | ONS
Imfinzi Duravalumab Injection, 500 mg/10 mL at Rs 8999/box in New Delhi | ID: 2853132773630
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC - ScienceDirect
Reimagining Treatment for Unresectable Stage III Non-Small Cell Lung Cancer - Cancer Therapy Advisor
Immune-checkpoint inhibitors: long-term implications of toxicity | Nature Reviews Clinical Oncology
Long-Term Side Effects of Immune Checkpoint Inhibitors - NCI
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer | Future Oncology
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial ...
IJMS | Free Full-Text | Infections and Immunotherapy in Lung Cancer: A Bad Relationship?
Frontiers | Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
Immunotherapy and its side effects | Cancer Research UK
Durvalumab Side Effects: Common, Severe, Long Term
Did You Know – IMFINZI® (durvalumab) for unresectable Stage 3 NSCLC
Tremelimumab/Durvalumab Plus Chemo Improves Survival in Metastatic NSCLC
Side-effects of Short Term and Long Term Glucocortcoid Use | Download Table
Biomedicines | Free Full-Text | Adverse Events and Tolerability of Combined Durvalumab and Tremelimumab versus Durvalumab Alone in Solid Cancers: A Systematic Review and Meta-Analysis
Durvalumab (Imfinzi) Drug Information
Reported adverse events in 39 patients with stage III NSCLC during | Download Scientific Diagram
Durvalumab (Imfinzi) Drug Information
